ECLS

Verde Announces Q4 and FY 2023 Results

Retrieved on: 
Thursday, March 28, 2024
Potassium chloride, Farmer, Central bank, FY, CNM, Risk, Global warming potential, History, ECLS, Carbon, Carbon dioxide, Fertilizer, Depreciation, Weather

SINGAPORE, March 28, 2024 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) announces its financial results for the full year ended December 31, 2023 (“FY 2023”) and the fourth quarter 2023 (“Q4 2023”), as audited by Ernst & Young (“EY”). The FY 2023 audited results were consistent with the interim results announced by the Company on January 26, 2024:

Key Points: 
  • Verde's revenue amounted to $37.9 million in FY 2023, a 53% decrease compared to the previous year, when potash prices reached record levels.
  • The Company reported a net loss of $6.0 million in FY 2023, compared to a net profit of $17.8 million in FY 2022.
  • Canadian dollar devaluated by 7% versus Brazilian Real in FY 2023 compared to FY 2022.
  • The Company will host a conference call on Tuesday, April 02, 2024, at 10:00 am Eastern Time, to discuss Q4 and FY 2023 results and provide an update.

Bay Area Lyme Foundation Now Accepting Applications for 2024 Emerging Leader Award and Grant

Retrieved on: 
Thursday, October 26, 2023
ISCB Senior Scientist Award, Lyme disease, Associate, Principal investigator, Therapy, University of California, San Francisco, MD, Doctor of Philosophy, ELA, Research, Emerging, Private sector, Bangladesh Technical Education Board, Stanford University, Brandeis University, University, Massachusetts Institute of Technology, NIH, San Francisco, Pacific Time Zone, Virginia Tech, ECLS, Hospital, Harvard University, Louisiana State University, Boston Children's Hospital, Infection, Letter, Pharmaceutical industry

This year, the Foundation ELA will present a $150,000 award for a researcher who is at the post-doctoral level through associate professor level.

Key Points: 
  • This year, the Foundation ELA will present a $150,000 award for a researcher who is at the post-doctoral level through associate professor level.
  • Even today, it presents a significant hurdle for the scientific research community,” said Wendy Adams, research grant director Bay Area Lyme Foundation.
  • Bay Area Lyme Foundation encourages researchers to explore novel, scientifically well-founded concepts with potential utility toward that goal.
  • Many ELA recipients have subsequently received grants from other groups including the NIH, as well as continued support from Bay Area Lyme Foundation.

By Mimicking Nature, Scientists Build a Better Artificial Lung

Retrieved on: 
Tuesday, May 30, 2023
Fort Detrick, Heart, Respiratory failure, American Society for Artificial Internal Organs, Advanced Science, Bleeding, Bed, Code, Oxygen, Extracorporeal membrane oxygenation, Critical care, ECMO, Research, Coagulopathy, Biomaterial, Carbon, Bangladesh Technical Education Board, Assistant, Lung, Microfluidics, Acquisition, Animal, Patient, ECLS, Blood, Department of Defense Serum Repository, Draper, Paper, Nursing care plan, ICU, Human body, Trauma, Society, Assistant Secretary of Defense for Health Affairs, United States Department of Agriculture, Pneumonia, Safety, AREVA, Medical device, Medical imaging, Defense

CAMBRIDGE, Mass., May 30, 2023 /PRNewswire-PRWeb/ -- A mechanical device for oxygenating blood outside the human body, essentially functioning as an artificial lung, is taking a leap forward fifty years after its debut. The original device in clinical use today, called ECMO, which stands for extracorporeal membrane oxygenation, has been reimagined by bioengineers at Draper who took their cues from the way the human body oxygenates blood in the branching circulatory system.

Key Points: 
  • By mimicking blood flow patterns in the human body, engineers improve the safety and efficacy of artificial lungs, a potential benefit to critical care patients and combat casualties.
  • CAMBRIDGE, Mass., May 30, 2023 /PRNewswire-PRWeb/ -- A mechanical device for oxygenating blood outside the human body, essentially functioning as an artificial lung, is taking a leap forward fifty years after its debut.
  • Critical care patients such as premature infants, transplant and pneumonia patients and others suffering respiratory failure and related conditions may benefit, he added.
  • Opinions, interpretations, conclusions, and recommendations contained herein are those of the author(s) and are not necessarily endorsed by the Department of Defense.

Eurosets and Estor announce a strategic partnership for the exclusive distribution of Polymyxin B hemoperfusion therapy in France, Belgium, Netherlands, Luxemburg and Austria

Retrieved on: 
Friday, April 28, 2023
Partnership, ECMO, Polymyxin, Literature, Polymyxin B, Patient, ECLS, Blood, Pharmaceutical industry, Hospital, Medical device, Euroset

This strategic alliance between Eurosets and Estor will further contribute to the advancement of Polymyxin B hemoperfusion therapy, both in the area of post-cardiac surgery and in the general intensive care itself, so that Polymyxin B hemoperfusion can be available to a larger patient population in Europe.

Key Points: 
  • This strategic alliance between Eurosets and Estor will further contribute to the advancement of Polymyxin B hemoperfusion therapy, both in the area of post-cardiac surgery and in the general intensive care itself, so that Polymyxin B hemoperfusion can be available to a larger patient population in Europe.
  • Polymyxin B hemoperfusion is the reference complementary therapy for neutralizing endotoxin in human blood, combining the unique properties of Polymyxin B and blood purification therapy.
  • More than 250,000 patients have been treated with Polymyxin B hemoperfusion therapy worldwide and more than 400 peer-reviewed articles are available in the literature.
  • “This strategic alliance between Eurosets and Estor represents a milestone that will contribute further to Polymyxin B hemoperfusion advancement in post-cardiac surgery and general intensive care for the benefit of patients in Europe,” said Dr. Mattia Corrado Bellaviti, CEO Estor.

Eurosets Announces First Patient Treated With Colibrì, the Lightest Extracorporeal Life Support System

Retrieved on: 
Wednesday, December 14, 2022
Medical Devices, Health, Surgery, Other Health, Cardiology, Biotechnology, Arnaud, Villeneuve, ICU, Cardiac arrest, Patient, Patient safety, Extracorporeal membrane oxygenation, ECMO, Multimedia, MCS, ECLS, Hospital, Heart, Medical device, Euroset

Eurosets, a company based in Medolla (Italy) leader in the development, production and commercialization of advanced medical devices, announces the first patient treated with Colibr, the lightest extracorporeal life support (ECLS) system available in the market.

Key Points: 
  • Eurosets, a company based in Medolla (Italy) leader in the development, production and commercialization of advanced medical devices, announces the first patient treated with Colibr, the lightest extracorporeal life support (ECLS) system available in the market.
  • The patient was supported on VA-ECMO and successfully weaned after few days of treatment.
  • I truly believe that Colibr has the potential to become the new standard of care for ECLS said Dr. Gaudard .
  • The breakthrough device developed by Eurosets is also the only one equipped with a wi-fi connection that allows innovative remote monitoring, thereby ensuring greater patient safety and easier management for healthcare professionals.

University of Phoenix Highlights Ethics and Fraud Prevention Practices During Fraud Awareness Week

Retrieved on: 
Monday, November 14, 2022
Environment, Online Privacy, Technology, Security, Professional Services, Sustainability, DEI (Diversity, Equity and Inclusion), Continuing, University, Education, ACFE, Student, Communication, Certified Fraud Examiner, Task force, Association of Certified Fraud Examiners, Nation, Ethics & Compliance Initiative, ECLS, Code, SPHR, University of Phoenix, Fear, ECDP, Careers New Zealand, University, Fraud, ECI, Information, Audit, Management, Ethics

University of Phoenix is committed to fraud prevention, detection, and awareness and is proud to be an official supporter of the Association of Certified Fraud Examiners (ACFE)s 2022 International Fraud Awareness Week, Nov. 13-19, 2022.

Key Points: 
  • University of Phoenix is committed to fraud prevention, detection, and awareness and is proud to be an official supporter of the Association of Certified Fraud Examiners (ACFE)s 2022 International Fraud Awareness Week, Nov. 13-19, 2022.
  • University of Phoenixs approach to fraud prevention is grounded in its Code of Ethics and the University has established a robust system of internal controls, including embedding key departments within its finance and student service departments to prevent, detect, and generate awareness on fraud schemes.
  • According to the ACFE's 2022 Report to the Nations on Occupational Fraud , proactive efforts to reduce and detect fraud results in quicker detection and lower losses.
  • The Code of Ethics guides university best practices from fraud prevention to ethics , and from sustainability to diversity, equity, inclusion and belonging .

Press Release: PANOLIN signs agreement to sell ECL business to Shell

Retrieved on: 
Thursday, November 3, 2022
OEM, AG, Shell, CEO, General manager, Intellectual property, Lubricant, Sale, Technology, ECLS, ECL, Environment, Royal Dutch Shell

Madetswil, 2 November 2022 Wholly-owned subsidiaries of Shell plc (Shell) in Switzerland, the UK, US and Sweden (Shell (Switzerland) AG, Shell U.K. Limited, Pennzoil-Quaker State Company and Shell Aviation Sweden AB) have entered into agreements to acquire the Environmentally Considerate Lubricants (ECLs) business of the PANOLIN Group.

Key Points: 
  • Madetswil, 2 November 2022 Wholly-owned subsidiaries of Shell plc (Shell) in Switzerland, the UK, US and Sweden (Shell (Switzerland) AG, Shell U.K. Limited, Pennzoil-Quaker State Company and Shell Aviation Sweden AB) have entered into agreements to acquire the Environmentally Considerate Lubricants (ECLs) business of the PANOLIN Group.
  • Following completion of the transaction, Shell will manufacture, distribute and market the PANOLIN portfolio of ECL products alongside its established Shell Naturelle branded products.
  • All PANOLIN staff who currently support the ECL business in Switzerland, the UK, US and Sweden are expected to join Shell.
  • With the sale of the ECL business to Shell, the long-standing vision of the Lmmle family, for the PANOLIN brand to reach higher visibility and a global reach will be realized.

Eurosets Presents Colibrì, the Lightest and Most Compact ECLS System in the Market Which May Be Transported Even in a Backpack

Retrieved on: 
Thursday, October 6, 2022
Health, Medical Devices, Technology, Surgery, Health Technology, Mobile, Wireless, Cardiology, ECLS, ECMO, Achievement, Patient, Standard of care, MCS, Multimedia, Association, CEO, Adult, Patient safety, Heart, Cardiac arrest, European Association for Cardio-Thoracic Surgery, Extracorporeal membrane oxygenation, Management, Medical device, Euroset

Featuring a fully magnetic-levitating centrifugal pump that covers adult, paediatric and new-born patients, a series of advanced monitoring capabilities, and a complete integration with ECMOLife, Colibr is the lightest device available in the market.

Key Points: 
  • Featuring a fully magnetic-levitating centrifugal pump that covers adult, paediatric and new-born patients, a series of advanced monitoring capabilities, and a complete integration with ECMOLife, Colibr is the lightest device available in the market.
  • The breakthrough device developed by Eurosets is also the only one equipped with a wi-fi connection that allows innovative remote monitoring, thereby ensuring greater patient safety and easier management for healthcare professionals.
  • "Our vision is to reimagine ECLS treatments while responding to diverse medical needs through meaningful innovation and Colibr is fully in line with these core beliefs."
  • For more information about Colibr please contact your local Eurosets representative or visit site.

Inspira Technologies Applauded by Frost & Sullivan for Minimizing the Need for Invasive Mechanical Ventilation with Its Innovative Technology, the ART™ System

Retrieved on: 
Monday, February 28, 2022
Health, Achievement, ART, Extracorporeal membrane oxygenation, Hospital, Industry, Proton Inspira, Industry analyst, ECMO, ECLS, Food, Oxygen, Coma, Frost & Sullivan, Leadership, Frost, FDA, US Foods, Blood, Nasdaq, SAN, Class, MV, Patient, ICU, PMA, Management, Medical device, Medicine

SAN ANTONIO, Feb. 28, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European artificial respiratory market and, based on its findings, recognizes Inspira Technologies (Nasdaq: IINN/IINNW) with the 2021 Europe Technology Innovation Leadership Award. The company provides innovative medical technologies in the respiratory care industry. Inspira's ART system, a proprietary, early extracorporeal respiratory support system that elevates oxygen saturation levels, is designed to be a new standard of care as a second-line treatment to minimize the need for invasive mechanical ventilation (MV). The system leverages Inspira Technologies' hemo-protective low-flow technology, which rebalances patients' saturation levels while they are awake and spontaneously breathing.

Key Points: 
  • Inspira Technologies aims to set a new standard of care in the respiratory care industry by introducing its ART system.
  • The system leverages Inspira Technologies' hemo-protective low-flow technology, which rebalances patients' saturation levels while they are awake and spontaneously breathing.
  • "Inspira Technologies' ART system differs significantly from extracorporeal membrane oxygenation (ECMO) in many areas, including its intent of use, patient population, system size, and potential risks for the patient," noted Debarati Sengupta, Industrial Analyst at Frost & Sullivan.
  • Alternative treatments, such as invasive mechanical ventilation, can be applied alongside the ART system if a patient's health continues to deteriorate.

Inspira Technologies Applauded by Frost & Sullivan for Minimizing the Need for Invasive Mechanical Ventilation with Its Innovative Technology, the ART™ System

Retrieved on: 
Monday, February 28, 2022
Health, Achievement, ART, Extracorporeal membrane oxygenation, Hospital, Industry, Proton Inspira, Industry analyst, ECMO, ECLS, Food, Oxygen, Coma, Frost & Sullivan, Leadership, Frost, FDA, US Foods, Blood, Nasdaq, SAN, Class, MV, Patient, ICU, PMA, Management, Medical device, Medicine

SAN ANTONIO, Feb. 28, 2022 /PRNewswire/ -- Frost & Sullivan recently analyzed the European artificial respiratory market and, based on its findings, recognizes Inspira Technologies (Nasdaq: IINN/IINNW) with the 2021 Europe Technology Innovation Leadership Award. The company provides innovative medical technologies in the respiratory care industry. Inspira's ART system, a proprietary, early extracorporeal respiratory support system that elevates oxygen saturation levels, is designed to be a new standard of care as a second-line treatment to minimize the need for invasive mechanical ventilation (MV). The system leverages Inspira Technologies' hemo-protective low-flow technology, which rebalances patients' saturation levels while they are awake and spontaneously breathing.

Key Points: 
  • Inspira Technologies aims to set a new standard of care in the respiratory care industry by introducing its ART system.
  • The system leverages Inspira Technologies' hemo-protective low-flow technology, which rebalances patients' saturation levels while they are awake and spontaneously breathing.
  • "Inspira Technologies' ART system differs significantly from extracorporeal membrane oxygenation (ECMO) in many areas, including its intent of use, patient population, system size, and potential risks for the patient," noted Debarati Sengupta, Industrial Analyst at Frost & Sullivan.
  • Alternative treatments, such as invasive mechanical ventilation, can be applied alongside the ART system if a patient's health continues to deteriorate.